Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Paclitaxel (Taxol) is a chemotherapy drug that targets tubulin polymerization, leading to mitotic arrest and apoptosis.
• The tumor suppressor protein p53 plays a critical role in cellular responses to DNA damage and stress.
• Previous studies suggested that p53 loss confers resistance to DNA-damaging anticancer agents.

Purpose of the Study:

• To investigate the role of functional p53 in cellular sensitivity to paclitaxel.
• To elucidate the mechanisms underlying paclitaxel-induced cytotoxicity in cells with varying p53 levels.

Main Methods:

• Utilized normal human fibroblasts with functional p53 depletion (SV40 T antigen or HPV-16 E6) and primary embryo fibroblasts from p53 null mice.
• Assessed cytotoxicity, cell cycle progression (G2/M and G1 phases), and apoptosis induction following paclitaxel treatment.
• Monitored protein levels of p53 and p21cip1,waf1.

Main Results:

• Fibroblasts with reduced or absent p53 exhibited a 7- to 9-fold increase in paclitaxel-induced cytotoxicity.
• Lower p53 levels correlated with enhanced G2/M phase arrest, micronucleation, and p53-independent apoptosis.
• Surviving cells with intact p53 showed transient G1 accumulation with elevated p53 and p21cip1,waf1 protein levels.

Conclusions:

• Loss of functional p53 significantly enhances sensitivity to paclitaxel, contrary to findings with DNA-damaging agents.
• p53 status is a critical determinant of cellular response to paclitaxel-induced mitotic arrest and apoptosis.
• These findings have implications for understanding paclitaxel efficacy and developing personalized cancer therapies.